Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Ivabradine Prices Rise High Among Recent UK Launches In April

Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

Samsung Bioepis Biosimilars Report Sees Lower Price Boosting Uptake

Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.

Biosimilars Market Intelligence

Perindopril And Pramipexole Prices Peak In March

Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.

Market Intelligence Generic Drugs

The 10 US Biosimilar Launches That Could Drive Big Savings By 2027

Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Biosimilars United States

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is ‘doing better, but we still have improvements to make.’

Biosimilars United States

Wholesaler Hike Drives UK Price Spike In February

Increases by one particular wholesaler led to steep rises for a number of UK generics in February, according to market researcher WaveData.

Market Intelligence Generic Drugs

Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch

Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.

Biosimilars Sales & Earnings

New Pricing Policies Needed To Curb AMR Impact, States Industry Alliance Report

The AMR Industry Alliance has put forward six different policy proposals which it says could minimize the global impact of antimicrobial resistance.

Supply Chain Market Intelligence

Orion Bemoans Bad Luck In Winner-Takes-All Biosimilar Tenders

Finland’s Orion is continuing to await the potentially uplifting effect of its biosimilar partnership with Aurobindo’s CuraTeQ Biologics, after another tricky year.

Biosimilars Sales & Earnings
See All